Pharmaceuticals

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025

BOSTON, Jan. 21, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advance...

2025-01-22 11:01

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. * ASC30 oral tablet was generally safe and well ...

2025-01-21 19:00 1802

TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions and alignment with the U.S. Food and Drug Admin...

2025-01-21 15:30 1231

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...

2025-01-21 10:34 1849

MedAdvisor Solutions' helps pharmacists in Australia deliver more than 115,000 clinical services to patients through Expanded Scope of Practice Pilots in 2024

New case study showcases improved operational efficiency and patient care with enhanced workflow and clinical services for pharmacists MELBOURNE, Australia, Jan. 21, 2025 /PRNewswire/ -- MedAdvisor Solutions, a global leader in patient engagement and pharmacy technology, published its newest cas...

2025-01-21 07:22 1355

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT

TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc . (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 pat...

2025-01-20 21:44 2124

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®)has received marketing authorizatio...

2025-01-17 10:56 1694

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-01-17 08:00 4046

LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference

* New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" * Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing * Incheon Songdo Bio Campus Plant 1 Un...

2025-01-17 07:11 1775

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines ...

2025-01-17 07:00 2947

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent ...

2025-01-17 06:14 3315

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 17, 2025 /PRNewswire/ -- Concept Medical Inc. , a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the "MAGICAL BTK" (Randomized Controlled Trial of MagicTouch PTA – Siro...

2025-01-17 03:15 2101

Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the closing o...

2025-01-17 03:10 3132

SEACare 2025 - Your Gateway to Southeast Asia's Thriving Healthcare Market and Strategic Connections

Unlocking Opportunities in Southeast Asia's Healthcare Market KUALA LUMPUR, Malaysia, Jan. 16, 2025 /PRNewswire/ -- SEACare 2025, the Southeast Asia Healthcare & Pharma Show, returns for its 25th edition from 23 to 25 April 2025 at the Malaysian International Trade and Exhibition Centre (MIT...

2025-01-16 19:56 2424

BGI Genomics Empowers Brunei's National Cervical Cancer Prevention Program

SHENZHEN, China, Jan. 16, 2025 /PRNewswire/ -- On January 15, 2025, the Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics inBrunei, launched the National Cervical Cancer Prevention and Control Program along with the 2025 Nation...

2025-01-16 12:51 1907

(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology

TAICHUNG, Jan. 15, 2025 /PRNewswire/ -- On November 2, 2024, China Medical University (CMU) and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel Therapeutics to highlightTaiwan's advancements and explore new horizons in biomedical applications.Profes...

2025-01-16 09:00 1814

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-01-16 08:03 2636

Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

* Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 * Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug ...

2025-01-15 10:52 1612

Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference

- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Samsung...

2025-01-15 09:40 1717

Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology

AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE, Jan. 15, 2025 /PRNewswire/ -- Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in deliveri...

2025-01-15 09:00 1752
12345 ... 319